Sage Therapeutics Statistics Share Statistics Sage Therapeutics has 62.78M
shares outstanding. The number of shares has increased by 2.57%
in one year.
Shares Outstanding 62.78M Shares Change (YoY) 2.57% Shares Change (QoQ) 1.86% Owned by Institutions (%) 83.67% Shares Floating 51.31M Failed to Deliver (FTD) Shares 100 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 2.22M, so 3.54% of the outstanding
shares have been sold short.
Short Interest 2.22M Short % of Shares Out 3.54% Short % of Float 3.94% Short Ratio (days to cover) 1.24
Valuation Ratios The PE ratio is -0.82 and the forward
PE ratio is -3.21.
Sage Therapeutics's PEG ratio is
0.03.
PE Ratio -0.82 Forward PE -3.21 PS Ratio 8 Forward PS 4.5 PB Ratio 0.71 P/FCF Ratio -1.23 PEG Ratio 0.03
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Sage Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 7.42,
with a Debt / Equity ratio of 0.03.
Current Ratio 7.42 Quick Ratio 7.42 Debt / Equity 0.03 Debt / EBITDA -0.03 Debt / FCF -0.04 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $116.84K Profits Per Employee $-1.14M Employee Count 353 Asset Turnover 0.08 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 10.43% in the
last 52 weeks. The beta is 0.3, so Sage Therapeutics's
price volatility has been higher than the market average.
Beta 0.3 52-Week Price Change 10.43% 50-Day Moving Average 8.2 200-Day Moving Average 7.15 Relative Strength Index (RSI) 46.6 Average Volume (20 Days) 2,480,352
Income Statement In the last 12 months, Sage Therapeutics had revenue of 41.24M
and earned -400.67M
in profits. Earnings per share was -6.59.
Revenue 41.24M Gross Profit 31.8M Operating Income -432.37M Net Income -400.67M EBITDA -409.49M EBIT -410.52M Earnings Per Share (EPS) -6.59
Full Income Statement Balance Sheet The company has 81.02M in cash and 11.84M in
debt, giving a net cash position of 69.19M.
Cash & Cash Equivalents 81.02M Total Debt 11.84M Net Cash 69.19M Retained Earnings -2.97B Total Assets 422.92M Working Capital 364.44M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -267.19M
and capital expenditures 0, giving a free cash flow of -267.19M.
Operating Cash Flow -267.19M Capital Expenditures n/a Free Cash Flow -267.19M FCF Per Share -4.4
Full Cash Flow Statement Margins Gross margin is 77.1%, with operating and profit margins of -1048.35% and -971.48%.
Gross Margin 77.1% Operating Margin -1048.35% Pretax Margin -971.48% Profit Margin -971.48% EBITDA Margin -992.86% EBIT Margin -1048.35% FCF Margin -647.85%
